{"id":19310,"date":"2023-04-24T16:40:00","date_gmt":"2023-04-24T08:40:00","guid":{"rendered":"https:\/\/flcube.com\/?p=19310"},"modified":"2024-12-22T16:42:43","modified_gmt":"2024-12-22T08:42:43","slug":"yichang-hec-changjiang-pharmaceutical-reports-309-83-yoy-revenue-growth-in-2022-financials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19310","title":{"rendered":"YiChang HEC ChangJiang Pharmaceutical Reports 309.83% YOY Revenue Growth in 2022 Financials"},"content":{"rendered":"\n

YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558<\/a>), a China-based pharmaceutical company, has released its financial report for 2022, recording revenues of RMB 3.745 billion (USD 582.8 million), marking a substantial increase of 309.83% year-on-year (YOY). The company transitioned from a previous year loss to achieve net profits of RMB 76.6 million (USD 11.1 million). Research and development (R&D) expenditure for the period was RMB 199.2 million (USD 28.8 million), a decrease of 19.08% YOY.<\/p>\n\n\n\n

Core Product Sales and Therapy Performance<\/strong>
During the period, the company’s core product, the anti-influenza drug oseltamivir granules and capsules, generated a combined revenue of RMB 3.092 billion (USD 448.2 million), representing a significant increase of 450% YOY. Hypertension therapies telmisartan and olmesartan medoxomil contributed RMB 62.93 million (USD 9.1 million) and RMB 44.26 million (USD 6.4 million) respectively, with YOY increases of 26.65% and 19.14%. Gout therapy benzbromarone revenue reached RMB 98.42 million (USD 14.26 million), up 27.6% YOY.<\/p>\n\n\n\n

Marketing Approvals and Pipeline Progress<\/strong>
HEC obtained marketing approvals for metoprolol, azithromycin, Insulin Aspart, and Insulin Aspart 30 in 2022, demonstrating the company’s commitment to expanding its product offerings. The recombinant human insulin injection with protamine (pre-mixed 30R) is under domestic manufacturing registration review in China. RongliflozinL-Pyroglutamic Acid is currently in a Phase III study, and the liraglutide biosimilar is being prepared for market filing. As of December 31, 2022, 29 out of 33 generics acquired from Guangdong HEC Pharm have been approved for marketing in China.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558), a China-based pharmaceutical company, has released its…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,2358,859],"class_list":["post-19310","post","type-post","status-publish","format-standard","hentry","category-company","tag-finanical-reports","tag-hec-changjiang-pharmaceutical","tag-hkg-1558"],"yoast_head":"\nYiChang HEC ChangJiang Pharmaceutical Reports 309.83% YOY Revenue Growth in 2022 Financials - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558), a China-based pharmaceutical company, has released its financial report for 2022, recording revenues of RMB 3.745 billion (USD 582.8 million), marking a substantial increase of 309.83% year-on-year (YOY). The company transitioned from a previous year loss to achieve net profits of RMB 76.6 million (USD 11.1 million). Research and development (R&D) expenditure for the period was RMB 199.2 million (USD 28.8 million), a decrease of 19.08% YOY.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19310\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"YiChang HEC ChangJiang Pharmaceutical Reports 309.83% YOY Revenue Growth in 2022 Financials\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19310\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-24T08:40:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-22T08:42:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19310#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19310\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"YiChang HEC ChangJiang Pharmaceutical Reports 309.83% YOY Revenue Growth in 2022 Financials\",\"datePublished\":\"2023-04-24T08:40:00+00:00\",\"dateModified\":\"2024-12-22T08:42:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19310\"},\"wordCount\":232,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finanical Reports\",\"HEC ChangJiang Pharmaceutical\",\"HKG: 1558\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19310#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19310\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19310\",\"name\":\"YiChang HEC ChangJiang Pharmaceutical Reports 309.83% YOY Revenue Growth in 2022 Financials - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-04-24T08:40:00+00:00\",\"dateModified\":\"2024-12-22T08:42:43+00:00\",\"description\":\"YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558), a China-based pharmaceutical company, has released its financial report for 2022, recording revenues of RMB 3.745 billion (USD 582.8 million), marking a substantial increase of 309.83% year-on-year (YOY). The company transitioned from a previous year loss to achieve net profits of RMB 76.6 million (USD 11.1 million). Research and development (R&D) expenditure for the period was RMB 199.2 million (USD 28.8 million), a decrease of 19.08% YOY.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19310#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19310\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19310#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"YiChang HEC ChangJiang Pharmaceutical Reports 309.83% YOY Revenue Growth in 2022 Financials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"YiChang HEC ChangJiang Pharmaceutical Reports 309.83% YOY Revenue Growth in 2022 Financials - Insight, China's Pharmaceutical Industry","description":"YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558), a China-based pharmaceutical company, has released its financial report for 2022, recording revenues of RMB 3.745 billion (USD 582.8 million), marking a substantial increase of 309.83% year-on-year (YOY). The company transitioned from a previous year loss to achieve net profits of RMB 76.6 million (USD 11.1 million). Research and development (R&D) expenditure for the period was RMB 199.2 million (USD 28.8 million), a decrease of 19.08% YOY.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19310","og_locale":"en_US","og_type":"article","og_title":"YiChang HEC ChangJiang Pharmaceutical Reports 309.83% YOY Revenue Growth in 2022 Financials","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=19310","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-04-24T08:40:00+00:00","article_modified_time":"2024-12-22T08:42:43+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19310#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19310"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"YiChang HEC ChangJiang Pharmaceutical Reports 309.83% YOY Revenue Growth in 2022 Financials","datePublished":"2023-04-24T08:40:00+00:00","dateModified":"2024-12-22T08:42:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19310"},"wordCount":232,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finanical Reports","HEC ChangJiang Pharmaceutical","HKG: 1558"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19310#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19310","url":"https:\/\/flcube.com\/?p=19310","name":"YiChang HEC ChangJiang Pharmaceutical Reports 309.83% YOY Revenue Growth in 2022 Financials - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-04-24T08:40:00+00:00","dateModified":"2024-12-22T08:42:43+00:00","description":"YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558), a China-based pharmaceutical company, has released its financial report for 2022, recording revenues of RMB 3.745 billion (USD 582.8 million), marking a substantial increase of 309.83% year-on-year (YOY). The company transitioned from a previous year loss to achieve net profits of RMB 76.6 million (USD 11.1 million). Research and development (R&D) expenditure for the period was RMB 199.2 million (USD 28.8 million), a decrease of 19.08% YOY.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19310#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19310"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19310#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"YiChang HEC ChangJiang Pharmaceutical Reports 309.83% YOY Revenue Growth in 2022 Financials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19310","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19310"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19310\/revisions"}],"predecessor-version":[{"id":19311,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19310\/revisions\/19311"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19310"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19310"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19310"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}